• Markets
    • icon
  • Companies
OCC · ASX

Orthocell Ltd (ASX:OCC)

AU$0.38

 0.005 (1.316%)
ASX:Live
26/07/2024 04:10:15 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OCC Overview

OCC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Neutral

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About OCC

Website

Orthocell Ltd

Telephone

61.8.9360.2888

Address

Building 191 90 South Street Murdoch University Murdoch, Western Australia (WA) 6150

Description

Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.

OCC Price Chart

Key Stats

Market Cap

AU$81.64M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.32 - 0.46

Trade Value (12mth)

AU$13,506.00

1 week

-2.56%

1 month

4.11%

YTD

-6.17%

1 year

-1.3%

All time high

0.99

Key Fundamentals

EPS 3 yr Growth

-11.900%

EBITDA Margin

-229.90%

Operating Cashflow

$15m

Free Cash Flow Return

173.50%

ROIC

-74.30%

Interest Coverage

-319.10

Quick Ratio

5.70

Other Data

Shares on Issue (Fully Dilluted)

199m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.03

OCC Announcements

Latest Announcements

Date Announcements

24 July 24

Global Market Expansion Accelerates - New Regions Pending

×

Global Market Expansion Accelerates - New Regions Pending

16 July 24

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

11 July 24

Regulatory Approval to Commence Sales for Striate in Canada

×

Regulatory Approval to Commence Sales for Striate in Canada

10 July 24

Pause in Trading

×

Pause in Trading

10 July 24

Trading Halt

×

Trading Halt

09 July 24

Record Quarterly and Yearly Revenue Show Outstanding Growth

×

Record Quarterly and Yearly Revenue Show Outstanding Growth

12 June 24

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

11 June 24

Third Revenue Generating Product to be Launched in SmrtGraft

×

Third Revenue Generating Product to be Launched in SmrtGraft

11 June 24

Proposed issue of securities - OCC

×

Proposed issue of securities - OCC

05 June 24

Notification of cessation of securities - OCC

×

Notification of cessation of securities - OCC

14 May 24

Outstanding 98.6% Success Rate in Striate Implant Study

×

Outstanding 98.6% Success Rate in Striate Implant Study

30 April 24

Compelling 85% Success Rate Remplir Study now published

×

Compelling 85% Success Rate Remplir Study now published

24 April 24

Securities Trading Policy

×

Securities Trading Policy

24 April 24

Change of Director's Interest Notice-John Van Der Wielen

×

Change of Director's Interest Notice-John Van Der Wielen

16 April 24

Change of Director's Interest Notice-John Van Der Wielen

×

Change of Director's Interest Notice-John Van Der Wielen

15 April 24

Orthocell receives $3.05m R&D tax incentive refund

×

Orthocell receives $3.05m R&D tax incentive refund

08 April 24

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

25 March 24

Part 1 Remplir US Market Authorisation Successfully Complete

×

Part 1 Remplir US Market Authorisation Successfully Complete

11 March 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

11 March 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

11 March 24

Cleansing Notice

×

Cleansing Notice

28 February 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

28 February 24

Cleansing Notice

×

Cleansing Notice

23 February 24

Appendix 4D & Half-Year Financial Statements

×

Appendix 4D & Half-Year Financial Statements

22 February 24

Strategic Placement to Raise $3.5 million

×

Strategic Placement to Raise $3.5 million

OCC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.05 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.05 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.4 3.3 32.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.1 -89.7 61.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.3 -8.6 20.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.05 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.04 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.8 -46.1 -42.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 187 195 197 Lock Lock Lock
Basic m Lock Lock Lock Lock 187 195 197 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 1 2 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.5 50.5 177.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 12 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 1 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4,786.4 177.6 267.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 29.5 54.4 72.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 71 46 28 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.0 0.5 12.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,103.5 -729.6 -229.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -12 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.2 1.2 10.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,146.3 -752.4 -243.0 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -11 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -9 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.9 -0.8 31.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -887.8 -594.5 -147.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -6 15 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -7 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.1 -41.6 306.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4.7 -4.4 3.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 16 11 25 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 19 38 30 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -16 -11 -24 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 28 23 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 10 6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 17 10 7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -18.4 -40.8 -36.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -46.8 -24.0 -21.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -60.0 -82.6 -120.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -46.7 -65.8 -74.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -24.0 -45.3 173.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A -319.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.9 2.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.1 -106.2 -394.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.8 5.2 5.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.6 5.1 5.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 95.6 31.3 92.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -239.6 -91.8 322.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.9 0.1 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.8 1.3 1.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 87.7 214.3 20.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,123.0 -734.5 -221.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -59.1 -29.7 -31.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -46.8 -24.0 -21.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 3.8 4.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 131.3 282.5 254.3 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 92.7 2,837.0 1,049.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 224.0 3,119.6 1,303.4 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 269.5 902.8 473.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -45.5 2,216.8 830.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.03%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

-0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OCC Shortsell

Frequently Asked Questions

The current share price of Orthocell Ltd (OCC:ASX) is AU$0.38.
The 52-week high share price for Orthocell Ltd (OCC:ASX) is AU$0.46.
The 52-week low share price for Orthocell Ltd (OCC:ASX)? is AU$0.32.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not offer franking credits.
Orthocell Ltd (OCC:ASX) is classified in the Healthcare.
The current P/E ratio for Orthocell Ltd (OCC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.